ReCOV

ReCOV is a COVID-19 vaccine candidate developed by Jiangsu Rec-Biotechnology Co Ltd.^[1]^[2]^[3]^[4]

References

^ Clinical trial number NCT04818801 for "Safety, Reactogenicity and Immunogenicity Study of ReCOV" at ClinicalTrials.gov
^ Clinical trial number NCT05084989 for "Efficacy, Safety, and Immunogenicity Study of the Recombinant Two-component COVID-19 Vaccine (CHO Cell) (ReCOV)" at ClinicalTrials.gov
^ Allott A, McDonald L (24 June 2021). "New Covid-19 vaccine developed in China is being tested on Kiwis". Stuff. Retrieved 23 December 2021.
^ "Coronavirus: China-made 'ReCov' vaccine may be better than Pfizer-BioNTech's, New Zealand doctor says; Sydney faces 'scariest period' of pandemic". South China Morning Post. 24 June 2021. Retrieved 23 December 2021.

This article about COVID-19 vaccines is a stub. You can help Wikipedia by expanding it.

This article about vaccines or vaccination is a stub. You can help Wikipedia by expanding it.